APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sickle Cell Anemia Therapeutics

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Selected research

Market Analysis & Forecast

Global Sickle Cell Anemia Therapeutics Market Analysis and Forecast 2026-2032

21 December 2025196 pages

Choose your research edition.

Industry ResearchSickle Cell Anemia Therapeutics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Sickle Cell Anemia Therapeutics Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Sickle Cell Anemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sickle Cell Anemia Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Sickle Cell Anemia Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.

Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.

Read the full market overview

In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.

Report Includes

This report presents an overview of global market for Sickle Cell Anemia Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Sickle Cell Anemia Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Sickle Cell Anemia Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Sickle Cell Anemia Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Sickle Cell Anemia Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Sickle Cell Anemia Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Sickle Cell Anemia Therapeutics Segment by Company

Emmaus Medical

Addmedica

Gamida Cell

GlycoMimetics

Pfizer

Novartis

Global Blood Therapeutics

Micelle BioPharma

Bluebird Bio

Prolong Pharmaceuticals

Modus Therapeutics

Sangamo Biosciences

Bioverativ

Imara

Ironwood Pharmaceuticals

Sickle Cell Anemia Therapeutics Segment by Type

Blood Transfusion

Pharmacotherapy

Bone Marrow Transplant

Sickle Cell Anemia Therapeutics Segment by Application

Child

Adult

Sickle Cell Anemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Anemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Anemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Anemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Sickle Cell Anemia Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Sickle Cell Anemia Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sickle Cell Anemia Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Blood Transfusion Major Player Table 3. Pharmacotherapy Major Player Table 4. Bone Marrow Transplant Major Player Table 5. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Child Major Player Table 7. Adult Major Player Table 8. Sickle Cell Anemia Therapeutics Industry Trends Table 9. Sickle Cell Anemia Therapeutics Industry Drivers Table 10. Sickle Cell Anemia Therapeutics Industry Opportunities and Challenges Table 11. Sickle Cell Anemia Therapeutics Industry Restraints Table 12. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Sickle Cell Anemia Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Sickle Cell Anemia Therapeutics Market Share by Region (2021-2026) Table 15. Global Sickle Cell Anemia Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Sickle Cell Anemia Therapeutics Market Share by Region (2027-2032) Table 17. Global Sickle Cell Anemia Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Players (2021-2026) Table 19. Global Sickle Cell Anemia Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Sickle Cell Anemia Therapeutics Key Players Headquarters & Area Served Table 21. Global Sickle Cell Anemia Therapeutics Players, Product Type & Application Table 22. Global Sickle Cell Anemia Therapeutics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Sickle Cell Anemia Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Sickle Cell Anemia Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Sickle Cell Anemia Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Emmaus Medical Company Information Table 36. Emmaus Medical Business Overview Table 37. Emmaus Medical Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Emmaus Medical Sickle Cell Anemia Therapeutics Product Portfolio Table 39. Emmaus Medical Recent Development Table 40. Addmedica Company Information Table 41. Addmedica Business Overview Table 42. Addmedica Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Addmedica Sickle Cell Anemia Therapeutics Product Portfolio Table 44. Addmedica Recent Development Table 45. Gamida Cell Company Information Table 46. Gamida Cell Business Overview Table 47. Gamida Cell Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Gamida Cell Sickle Cell Anemia Therapeutics Product Portfolio Table 49. Gamida Cell Recent Development Table 50. GlycoMimetics Company Information Table 51. GlycoMimetics Business Overview Table 52. GlycoMimetics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. GlycoMimetics Sickle Cell Anemia Therapeutics Product Portfolio Table 54. GlycoMimetics Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer Sickle Cell Anemia Therapeutics Product Portfolio Table 59. Pfizer Recent Development Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Novartis Sickle Cell Anemia Therapeutics Product Portfolio Table 64. Novartis Recent Development Table 65. Global Blood Therapeutics Company Information Table 66. Global Blood Therapeutics Business Overview Table 67. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio Table 69. Global Blood Therapeutics Recent Development Table 70. Micelle BioPharma Company Information Table 71. Micelle BioPharma Business Overview Table 72. Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Micelle BioPharma Sickle Cell Anemia Therapeutics Product Portfolio Table 74. Micelle BioPharma Recent Development Table 75. Bluebird Bio Company Information Table 76. Bluebird Bio Business Overview Table 77. Bluebird Bio Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Bluebird Bio Sickle Cell Anemia Therapeutics Product Portfolio Table 79. Bluebird Bio Recent Development Table 80. Prolong Pharmaceuticals Company Information Table 81. Prolong Pharmaceuticals Business Overview Table 82. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio Table 84. Prolong Pharmaceuticals Recent Development Table 85. Modus Therapeutics Company Information Table 86. Modus Therapeutics Business Overview Table 87. Modus Therapeutics Sickle Cell Anemia Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Modus Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio Table 89. Modus Therapeutics Recent Development Table 90. Sangamo Biosciences Company Information Table 91. Sangamo Biosciences Business Overview Table 92. Sangamo Biosciences Sickle Cell Anemia Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Sangamo Biosciences Sickle Cell Anemia Therapeutics Product Portfolio Table 94. Sangamo Biosciences Recent Development Table 95. Bioverativ Company Information Table 96. Bioverativ Business Overview Table 97. Bioverativ Sickle Cell Anemia Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Bioverativ Sickle Cell Anemia Therapeutics Product Portfolio Table 99. Bioverativ Recent Development Table 100. Imara Company Information Table 101. Imara Business Overview Table 102. Imara Sickle Cell Anemia Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Imara Sickle Cell Anemia Therapeutics Product Portfolio Table 104. Imara Recent Development Table 105. Ironwood Pharmaceuticals Company Information Table 106. Ironwood Pharmaceuticals Business Overview Table 107. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio Table 109. Ironwood Pharmaceuticals Recent Development Table 110. North America Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 111. North America Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 112. North America Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Sickle Cell Anemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Sickle Cell Anemia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Sickle Cell Anemia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe Sickle Cell Anemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Sickle Cell Anemia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe Sickle Cell Anemia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 124. China Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 125. China Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 126. China Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 127. China Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Sickle Cell Anemia Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Sickle Cell Anemia Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia Sickle Cell Anemia Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA Sickle Cell Anemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA Sickle Cell Anemia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA Sickle Cell Anemia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Sickle Cell Anemia Therapeutics Image Figure 2. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sickle Cell Anemia Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Blood Transfusion Image Figure 5. Pharmacotherapy Image Figure 6. Bone Marrow Transplant Image Figure 7. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Sickle Cell Anemia Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Child Image Figure 10. Adult Image Figure 11. Global Sickle Cell Anemia Therapeutics Market Size (US$ Million) & (2021-2032) Figure 12. Global Sickle Cell Anemia Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Sickle Cell Anemia Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Sickle Cell Anemia Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Sickle Cell Anemia Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Sickle Cell Anemia Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2021-2032) Figure 19. Global Sickle Cell Anemia Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Sickle Cell Anemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032) Figure 24. North America Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032) Figure 25. North America Sickle Cell Anemia Therapeutics Revenue Share by Country (2021-2032) Figure 26. United States Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Sickle Cell Anemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032) Figure 31. Europe Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032) Figure 32. Europe Sickle Cell Anemia Therapeutics Revenue Share by Country (2021-2032) Figure 33. Germany Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Sickle Cell Anemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032) Figure 43. China Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032) Figure 44. Asia Sickle Cell Anemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032) Figure 46. Asia Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Sickle Cell Anemia Therapeutics Revenue Share by Region (2021-2032) Figure 48. Japan Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Sickle Cell Anemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032) Figure 56. SAMEA Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032) Figure 57. SAMEA Sickle Cell Anemia Therapeutics Revenue Share by Country (2021-2032) Figure 58. Brazil Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Sickle Cell Anemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant
Applications
  • Child
  • Adult
Companies covered
  • Emmaus Medical
  • Addmedica
  • Gamida Cell
  • GlycoMimetics
  • Pfizer
  • Novartis
  • Global Blood Therapeutics
  • Micelle BioPharma
  • Bluebird Bio
  • Prolong Pharmaceuticals
  • Modus Therapeutics
  • Sangamo Biosciences
  • Bioverativ
  • Imara
  • Ironwood Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Sickle Cell Anemia Therapeutics Market by Type
  3. 1.2.1 Global Sickle Cell Anemia Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Blood Transfusion
  5. 1.2.3 Pharmacotherapy
  6. 1.2.4 Bone Marrow Transplant
  7. 1.3 Sickle Cell Anemia Therapeutics Market by Application
  8. 1.3.1 Global Sickle Cell Anemia Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Child
  10. 1.3.3 Adult
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Sickle Cell Anemia Therapeutics Market Dynamics
  1. 2.1 Sickle Cell Anemia Therapeutics Industry Trends
  2. 2.2 Sickle Cell Anemia Therapeutics Industry Drivers
  3. 2.3 Sickle Cell Anemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Sickle Cell Anemia Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Sickle Cell Anemia Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Sickle Cell Anemia Therapeutics Growth Trends by Region
  3. 3.2.1 Global Sickle Cell Anemia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Sickle Cell Anemia Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Sickle Cell Anemia Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Sickle Cell Anemia Therapeutics Revenue by Players
  2. 4.1.1 Global Sickle Cell Anemia Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Sickle Cell Anemia Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Sickle Cell Anemia Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Sickle Cell Anemia Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Sickle Cell Anemia Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Sickle Cell Anemia Therapeutics Players, Product Type & Application
  8. 4.5 Global Sickle Cell Anemia Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Sickle Cell Anemia Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Sickle Cell Anemia Therapeutics Tier 1, Tier 2, and Tier 3
5 Sickle Cell Anemia Therapeutics Market Size by Type
  1. 5.1 Global Sickle Cell Anemia Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Sickle Cell Anemia Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2021-2032)
6 Sickle Cell Anemia Therapeutics Market Size by Application
  1. 6.1 Global Sickle Cell Anemia Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Sickle Cell Anemia Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Emmaus Medical
  2. 7.1.1 Emmaus Medical Company Information
  3. 7.1.2 Emmaus Medical Business Overview
  4. 7.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Product Portfolio
  6. 7.1.5 Emmaus Medical Recent Developments
  7. 7.2 Addmedica
  8. 7.2.1 Addmedica Company Information
  9. 7.2.2 Addmedica Business Overview
  10. 7.2.3 Addmedica Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Addmedica Sickle Cell Anemia Therapeutics Product Portfolio
  12. 7.2.5 Addmedica Recent Developments
  13. 7.3 Gamida Cell
  14. 7.3.1 Gamida Cell Company Information
  15. 7.3.2 Gamida Cell Business Overview
  16. 7.3.3 Gamida Cell Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Gamida Cell Sickle Cell Anemia Therapeutics Product Portfolio
  18. 7.3.5 Gamida Cell Recent Developments
  19. 7.4 GlycoMimetics
  20. 7.4.1 GlycoMimetics Company Information
  21. 7.4.2 GlycoMimetics Business Overview
  22. 7.4.3 GlycoMimetics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlycoMimetics Sickle Cell Anemia Therapeutics Product Portfolio
  24. 7.4.5 GlycoMimetics Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Sickle Cell Anemia Therapeutics Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Sickle Cell Anemia Therapeutics Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Global Blood Therapeutics
  38. 7.7.1 Global Blood Therapeutics Company Information
  39. 7.7.2 Global Blood Therapeutics Business Overview
  40. 7.7.3 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio
  42. 7.7.5 Global Blood Therapeutics Recent Developments
  43. 7.8 Micelle BioPharma
  44. 7.8.1 Micelle BioPharma Company Information
  45. 7.8.2 Micelle BioPharma Business Overview
  46. 7.8.3 Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Micelle BioPharma Sickle Cell Anemia Therapeutics Product Portfolio
  48. 7.8.5 Micelle BioPharma Recent Developments
  49. 7.9 Bluebird Bio
  50. 7.9.1 Bluebird Bio Company Information
  51. 7.9.2 Bluebird Bio Business Overview
  52. 7.9.3 Bluebird Bio Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bluebird Bio Sickle Cell Anemia Therapeutics Product Portfolio
  54. 7.9.5 Bluebird Bio Recent Developments
  55. 7.10 Prolong Pharmaceuticals
  56. 7.10.1 Prolong Pharmaceuticals Company Information
  57. 7.10.2 Prolong Pharmaceuticals Business Overview
  58. 7.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio
  60. 7.10.5 Prolong Pharmaceuticals Recent Developments
  61. 7.11 Modus Therapeutics
  62. 7.11.1 Modus Therapeutics Company Information
  63. 7.11.2 Modus Therapeutics Business Overview
  64. 7.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio
  66. 7.11.5 Modus Therapeutics Recent Developments
  67. 7.12 Sangamo Biosciences
  68. 7.12.1 Sangamo Biosciences Company Information
  69. 7.12.2 Sangamo Biosciences Business Overview
  70. 7.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Product Portfolio
  72. 7.12.5 Sangamo Biosciences Recent Developments
  73. 7.13 Bioverativ
  74. 7.13.1 Bioverativ Company Information
  75. 7.13.2 Bioverativ Business Overview
  76. 7.13.3 Bioverativ Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Bioverativ Sickle Cell Anemia Therapeutics Product Portfolio
  78. 7.13.5 Bioverativ Recent Developments
  79. 7.14 Imara
  80. 7.14.1 Imara Company Information
  81. 7.14.2 Imara Business Overview
  82. 7.14.3 Imara Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Imara Sickle Cell Anemia Therapeutics Product Portfolio
  84. 7.14.5 Imara Recent Developments
  85. 7.15 Ironwood Pharmaceuticals
  86. 7.15.1 Ironwood Pharmaceuticals Company Information
  87. 7.15.2 Ironwood Pharmaceuticals Business Overview
  88. 7.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio
  90. 7.15.5 Ironwood Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Sickle Cell Anemia Therapeutics Revenue (2021-2032)
  2. 8.2 North America Sickle Cell Anemia Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Sickle Cell Anemia Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Sickle Cell Anemia Therapeutics Revenue by Country
  11. 8.6.1 North America Sickle Cell Anemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Sickle Cell Anemia Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Sickle Cell Anemia Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Sickle Cell Anemia Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Sickle Cell Anemia Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Sickle Cell Anemia Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Sickle Cell Anemia Therapeutics Revenue by Country
  11. 9.6.1 Europe Sickle Cell Anemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Sickle Cell Anemia Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Sickle Cell Anemia Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Sickle Cell Anemia Therapeutics Revenue (2021-2032)
  2. 10.2 China Sickle Cell Anemia Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Sickle Cell Anemia Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Sickle Cell Anemia Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Sickle Cell Anemia Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Sickle Cell Anemia Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Sickle Cell Anemia Therapeutics Revenue by Country
  11. 11.6.1 Asia Sickle Cell Anemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Sickle Cell Anemia Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Sickle Cell Anemia Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Sickle Cell Anemia Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Sickle Cell Anemia Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Sickle Cell Anemia Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Sickle Cell Anemia Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Sickle Cell Anemia Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Sickle Cell Anemia Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Sickle Cell Anemia Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Sickle Cell Anemia Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Sickle Cell Anemia Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Sickle Cell Anemia Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Sickle Cell Anemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Sickle Cell Anemia Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Sickle Cell Anemia Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst